Itziar Irurzun-Arana

Itziar Irurzun-Arana

Auto-generated profile, based on publicly available information

Itziar Irurzun-Arana

Pharmacometrics & Systems Pharmacology group, Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy and Nutrition, University of Navarra, Pamplona, Navarra, Spain

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in Trends in Pharmacological Sciences
Verified
Journal Article
Closed access
IIItziar Irurzun-Arana
Itziar Irurzun-Arana
CRChristopher Rackauckas
Christopher Rackauckas
TMThomas O. McDonald
Thomas O. McDonald
José Ignacio de TrocónizJosé Ignacio de Trocóniz
José Ignacio de Trocóniz

7 March 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
VBVioleta Balbas-Martinez
Violeta Balbas-Martinez
LRLeire Ruiz-Cerdá
Leire Ruiz-Cerdá
IIItziar Irurzun-Arana
Itziar Irurzun-Arana
IGIgnacio González-García
Ignacio González-García
AVAn Vermeulen
An Vermeulen
José Ignacio de TrocónizJosé Ignacio de Trocóniz
José Ignacio de Trocóniz
The literature on complex diseases is abundant but not always quantitative. This is particularly so for Inflammatory Bowel Disease (IBD), where many molecular pathways are qualitatively well described but this information cannot be used in traditional quantitative mathematical models employed in drug development. We propose the elaboration and validation of a logic network for IBD able to capture the information available in the literature that will facilitate the identification/validation of therapeutic targets. In this article, we propose a logic model for Inflammatory Bowel Disease (IBD) which consists of 43 nodes and 298 qualitative interactions. The model presented is able to describe the pathogenic mechanisms of the disorder and qualitatively describes the characteristic chronic inflammation. A perturbation analysis performed on the IBD network indicates that the model is robust. Also, as described in clinical trials, a simulation of anti-TNFα, anti-IL2 and Granulocyte and Monocyte Apheresis showed a decrease in the Metalloproteinases node (MMPs), which means a decrease in tissue damage. In contrast, as clinical trials have demonstrated, a simulation of anti-IL17 and anti-IFNγ or IL10 overexpression therapy did not show any major change in MMPs expression, as corresponds to a failed therapy. The model proved to be a promising in silico tool for the evaluation of potential therapeutic targets, the identification of new IBD biomarkers, the integration of IBD polymorphisms to anticipate responders and non-responders and can be reduced and transformed in quantitative model/s.

23 November 2016 in Bioinformatics
Verified
Journal Article
Closed access
PDF file
IIItziar Irurzun-Arana
Itziar Irurzun-Arana
JPJosé Martín Pastor
José Martín Pastor
José Ignacio de TrocónizJosé Ignacio de Trocóniz
José Ignacio de Trocóniz
JGJosé David Gómez-Mantilla
José David Gómez-Mantilla
Motivation: Literature on complex diseases is abundant but not always quantitative. Many molecular pathways are qualitatively well described but this information cannot be used in traditional quantitative mathematical models employed in drug development. Tools for analysis of discrete networks are useful to capture the available information in the literature but have not been efficiently integrated by the pharmaceutical industry. We propose an expansion of the usual analysis of discrete networks that facilitates the identification/validation of therapeutic targets. Results: In this article, we propose a methodology to perform Boolean modeling of Systems Biology/Pharmacology networks by using SPIDDOR (Systems Pharmacology for effIcient Drug Development On R) R package. The resulting models can be used to analyze the dynamics of signaling networks associated to diseases to predict the pathogenesis mechanisms and identify potential therapeutic targets. Availability and Implementation: The source code is available at https://github.com/SPIDDOR/SPIDDOR. Contact:itzirurzun@alumni.unav.es, itroconiz@unav.es Supplementary information:

1 October 2016 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
MRM. Leire Ruiz-Cerdá
M. Leire Ruiz-Cerdá
IIItziar Irurzun-Arana
Itziar Irurzun-Arana
IGIgnacio González-Garcia
Ignacio González-Garcia
CHChuanpu Hu
Chuanpu Hu
HZHonghui Zhou
Honghui Zhou
JGJosé David Gómez-Mantilla
José David Gómez-Mantilla

19 June 2020 in Cancer Research
Verified
Journal Article
Open access
PDF file
IIItziar Irurzun-Arana
Itziar Irurzun-Arana
TMThomas O. McDonald
Thomas O. McDonald
José Ignacio de TrocónizJosé Ignacio de Trocóniz
José Ignacio de Trocóniz
FMFranziska Michor
Franziska Michor
Identification of optimal schedules for combination drug administration relies on accurately estimating the correct pharmacokinetics, pharmacodynamics, and drug interaction effects. Misspecification of pharmacokinetics can lead to wrongly predicted timing or order of treatments, leading to schedules recommended on the basis of incorrect assumptions about absorption and elimination of a drug and its effect on tumor growth. Here, we developed a computational modeling platform and software package for combination treatment strategies with flexible pharmacokinetic profiles and multidrug interaction curves that are estimated from data. The software can be used to compare prespecified schedules on the basis of the number of resistant cells where drug interactions and pharmacokinetic curves can be estimated from user-provided data or models. We applied our approach to publicly available in vitro data of treatment with different tyrosine kinase inhibitors of BT-20 triple-negative breast cancer cells and of treatment with erlotinib of PC-9 non–small cell lung cancer cells. Our approach is publicly available in the form of an R package called ACESO (https://github.com/Michorlab/aceso) and can be used to investigate optimum dosing for any combination treatment. Significance: These findings introduce a computational modeling platform and software package for combination treatment strategies with flexible pharmacokinetic profiles and multidrug interaction curves that are estimated from data.

19 April 2018 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
IIItziar Irurzun-Arana
Itziar Irurzun-Arana
AJAlvaro Janda
Alvaro Janda
SASergio Ardanza-Trevijano
Sergio Ardanza-Trevijano
José Ignacio de TrocónizJosé Ignacio de Trocóniz
José Ignacio de Trocóniz
Numerous problems encountered in computational biology can be formulated as optimization problems. In this context, optimization of drug release characteristics or dosing schedules for anticancer agents has become a prominent area not only for the development of new drugs, but also for established drugs. However, in complex systems, optimization of drug exposure is not a trivial task and cannot be efficiently addressed through trial-error simulation exercises. Finding a solution to those problems is a challenging task which requires more advanced strategies like optimal control theory. In this work, we perform an optimal control analysis on a previously developed computational model for the testosterone effects of triptorelin in prostate cancer patients with the goal of finding optimal drug-release characteristics. We demonstrate how numerical control optimization of non-linear models can be used to find better therapeutic approaches in order to improve the final outcome of the patients. Mathematical models of the disease processes are widely used in computational biology to quantitatively describe the time course of disease progression and are often linked to pharmacokinetic–pharmacodynamic models in order to evaluate the effect of drug treatment on disease. Once the models are built from observed information and/or literature data, they can predict the dynamics of the system under different conditions through computer simulations. However, simulation exercises are not always effective to obtain the desired objectives due to the complexity of these systems. In this work, we optimized the release characteristics of a synthetic gonadotropin-releasing hormone analog used to induce chemical castration by inhibiting the testosterone levels in prostate cancer patients. The therapeutic goals to achieve were to minimize the initial flare up of testosterone levels and the time to reach testosterone values below castration limit, while maximizing the castration period of the patients. Our methodology, based on control theory, introduces a manipulable variable into the system’s equations to drive the model towards the established goals. We demonstrated how drug-release properties can be improved with the implementation of optimal control strategies to enhance the outcome of cancer patients. These methods are extrapolable to other problems encountered in the field.